Antileukemic effects of the combination of crenolanib and sorafenib in a MV4-11 xenograft AML mouse model. Female NSG mice engrafted with MV4-11-luc cells were treated with vehicle, crenolanib 15 mg/kg intraperitoneally, sorafenib 15 mg/kg orally, or crenolanib (15 mg/kg, intraperitoneally) plus sorafenib (15 mg/kg, orally) once daily (Monday to Friday) for 3 consecutive weeks beginning on day 17. (A-B) Leukemic cell bone marrow infiltration was monitored by noninvasive luciferase imaging (*P < .05; **P < .01; ***P < .001). (C) Kaplan-Meier analysis of animal survival (**P = .0017 for crenolanib vs vehicle; P = .0017 for sorafenib vs vehicle; P = .0017 for the drug combination versus vehicle; P = .0021 and P = .0026 for the drug combination vs crenolanib or sorafenib alone, respectively). Black bar denotes treatment period.